OrthoCor Medical conducted a study focused on the efficacy of their 27.12-MHz pulsed electromagnetic field (PEMF) device for soft tissue and joint pain. The results were quite promising, showing significant pain and medication reduction compared to standard-of-care treatments.
Why the Study Was Necessary
The primary reason for conducting this study was to find a safe and non-pharmacological alternative for pain management. Many people with chronic soft tissue and joint pain rely on medications, which can have side effects and lead to dependency. The hypothesis was that a specialized PEMF device could provide a superior, non-invasive option by directly targeting the source of the pain. By evaluating a specific frequency (27.12-MHz), the study aimed to demonstrate a more effective approach to PEMF therapy for pain management than general, unoptimized systems.
Key Takeaways from the Study
The clinical trial yielded three major findings:
Superior Pain Relief: The PEMF group experienced a 36% reduction in pain over 14 days, which was more than three times the 10% pain reduction seen in the standard-of-care (SOC) group.
Reduced Medication Use: Patients using PEMF therapy were able to decrease their medication use by an impressive 55%, while the SOC group only saw a 12% reduction.
Positive Crossover Results: In a "crossover" phase, patients who switched from SOC to PEMF saw an additional 18% decrease in pain and a 63% decrease in medication use, further reinforcing the effectiveness of the PEMF device.
These results validate the study's hypothesis that optimized PEMF therapy is a powerful tool for pain management, offering a better option than traditional methods.
How This Benefits Biel (BioElectronics Corp)
The study's findings are a significant boon for BioElectronics Corporation (BIEL), a company that specializes in wearable PEMF devices.
Market Validation: The study provides third-party clinical validation for the effectiveness of 27.12-MHz PEMF technology, which is the same frequency Biel uses in its products like the ActiPatch and RecoveryRx. This independent research strengthens Biel's claims and builds consumer and medical professional confidence in its product line. It's much more powerful to show a successful clinical trial from another company than to rely solely on your own proprietary research.
Enhanced Marketing and Sales: BIEL can leverage these results in its marketing materials to show its devices are based on scientifically proven technology. This can help drive sales and increase market share by distinguishing its products from other pain relief solutions that lack such rigorous clinical backing.
Expanding Use Cases: The study's focus on soft tissue and joint pain—a widespread issue—directly applies to Biel's target market. The data suggests that Biel's devices could be more widely adopted by clinics and recommended by doctors as a primary or supplementary non-pharmacological treatment for these common conditions.
Why the Study Was Necessary
The primary reason for conducting this study was to find a safe and non-pharmacological alternative for pain management. Many people with chronic soft tissue and joint pain rely on medications, which can have side effects and lead to dependency. The hypothesis was that a specialized PEMF device could provide a superior, non-invasive option by directly targeting the source of the pain. By evaluating a specific frequency (27.12-MHz), the study aimed to demonstrate a more effective approach to PEMF therapy for pain management than general, unoptimized systems.
Key Takeaways from the Study
The clinical trial yielded three major findings:
Superior Pain Relief: The PEMF group experienced a 36% reduction in pain over 14 days, which was more than three times the 10% pain reduction seen in the standard-of-care (SOC) group.
Reduced Medication Use: Patients using PEMF therapy were able to decrease their medication use by an impressive 55%, while the SOC group only saw a 12% reduction.
Positive Crossover Results: In a "crossover" phase, patients who switched from SOC to PEMF saw an additional 18% decrease in pain and a 63% decrease in medication use, further reinforcing the effectiveness of the PEMF device.
These results validate the study's hypothesis that optimized PEMF therapy is a powerful tool for pain management, offering a better option than traditional methods.
How This Benefits Biel (BioElectronics Corp)
The study's findings are a significant boon for BioElectronics Corporation (BIEL), a company that specializes in wearable PEMF devices.
Market Validation: The study provides third-party clinical validation for the effectiveness of 27.12-MHz PEMF technology, which is the same frequency Biel uses in its products like the ActiPatch and RecoveryRx. This independent research strengthens Biel's claims and builds consumer and medical professional confidence in its product line. It's much more powerful to show a successful clinical trial from another company than to rely solely on your own proprietary research.
Enhanced Marketing and Sales: BIEL can leverage these results in its marketing materials to show its devices are based on scientifically proven technology. This can help drive sales and increase market share by distinguishing its products from other pain relief solutions that lack such rigorous clinical backing.
Expanding Use Cases: The study's focus on soft tissue and joint pain—a widespread issue—directly applies to Biel's target market. The data suggests that Biel's devices could be more widely adopted by clinics and recommended by doctors as a primary or supplementary non-pharmacological treatment for these common conditions.
2
